Analysts Set Certara, Inc. (NASDAQ:CERT) PT at $15.92

Shares of Certara, Inc. (NASDAQ:CERT) have been assigned a consensus rating of “Hold” from the eight research firms that are covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $15.92.

Several research analysts have recently weighed in on the company. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Friday, September 27th. Robert W. Baird reduced their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Finally, Barclays dropped their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th.

Insider Activity

In other Certara news, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. This trade represents a 9.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.39% of the stock is owned by company insiders.

Institutional Investors Weigh In On Certara

A number of institutional investors and hedge funds have recently bought and sold shares of CERT. Blue Trust Inc. bought a new position in shares of Certara in the 2nd quarter worth $26,000. Innealta Capital LLC purchased a new position in Certara in the second quarter worth $36,000. KBC Group NV increased its stake in Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after acquiring an additional 1,584 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Certara during the second quarter valued at about $152,000. Finally, Algert Global LLC purchased a new position in shares of Certara in the 2nd quarter worth about $156,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Stock Performance

Shares of CERT stock opened at $10.85 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -54.25, a P/E/G ratio of 5.50 and a beta of 1.53. Certara has a 52 week low of $9.41 and a 52 week high of $19.87. The firm’s 50-day simple moving average is $10.82 and its two-hundred day simple moving average is $12.82.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter in the previous year, the firm posted $0.06 EPS. Certara’s revenue was up 10.7% on a year-over-year basis. As a group, equities analysts forecast that Certara will post 0.28 earnings per share for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.